Dr. Joshua Neumiller, Pharm D, CDE, FASCP
Washington State University
Dr. Josh Neumiller is Vice-Chair and Associate Professor in the Department of Pharmacotherapy at Washington State University. Dr Neumiller is a Certified Diabetes Educator (CDE) and a fellow of the American Society of Consultant Pharmacists. Josh is a contributing author for the ADA books Medications for the Treatment of Diabetes, Practical Insulin, and the American Diabetes Association Guide to Nutrition Therapy for Diabetes, and is the Editor-in Chief for the ADA journal Diabetes Spectrum. Josh’s research interests involve the management of diabetes and prevention of adverse drug events during transitions in care. Josh has practiced extensively in the geriatric community. Josh was recently awarded the 2016 Albert B. Prescott Pharmacy Leadership Award.
Friday September 8, 2017
AN UPDATE ON MEN’S HEALTH ISSUES
1. Review currently available drug therapies and considerations for the treatment of alopecia.
2. Discuss the symptoms and management of male hypogonadism and andropause.
3. Discuss treatment options and clinical considerations for men with benign prostatic hypertrophy (BPH).
4. Outline risk factors associated with erectile dysfunction and discuss the role of drug therapy in its treatment.
Saturday September 9, 2017
OSTEO AND RHEUMATOID ARTHRITIS
1. Identify the distinguishing characteristics of osteoarthritis (OA) and rheumatoid arthritis (RA).
2. List and discuss the risk factors for developing OA.
3. Review the medications commonly used to treat OA as well as their potential advantages, contraindications, and side effects.
4. List and understand the terms used to describe the extra-articular manifestations of RA.
5. Review the medications commonly used to treat RA as well as their potential advantages, contraindications, and side effects.
Sunday September 10, 2017
NEW DIABETES DRUGS & REVIEW OF DIABETIC NEUROPATHY
1. Review recently approved medications for the treatment of diabetes and their potential role in therapy.
2. Review select diabetes medications in the developmental pipeline.
3. Discuss potential safety considerations with new and emerging anti-diabetic medications.
4. Describe the pathophysiology of diabetic peripheral neuropathy (DPN) and discuss the impact on patients.
5. Outline currently available prescription and non-prescription treatment options for DPN.